Effect of perinatal zidovudine prophylaxis on the evolution of cell-free HIV-1 RNA in breast milk and on postnatal transmission.
Manigart, Olivier;
Crepin, Montcho;
Leroy, Valeriane;
Meda, Nicolas;
Valea, Diane;
Janoff, Edward N;
Rouet, Francois;
Dequae-Merchadoux, Laurence;
Dabis, Francois;
Rouzioux, Christine;
+2 more...Van de Perre, Philippe;
Diminution de la Transmission Mere-Enfant Study Group;
(2004)
Effect of perinatal zidovudine prophylaxis on the evolution of cell-free HIV-1 RNA in breast milk and on postnatal transmission.
The Journal of infectious diseases, 190 (8).
pp. 1422-1428.
ISSN 0022-1899
DOI: https://doi.org/10.1086/424569
Permanent Identifier
Use this Digital Object Identifier when citing or linking to this resource.
Perinatal zidovudine (ZDV) prophylaxis decreases rates of perinatal transmission of human immunodeficiency virus type 1 (HIV-1). Its relationship with levels of HIV-1 RNA in breast milk and postnatal transmission in breast-fed African children is unknown. At day 8 after delivery, levels of HIV-1 RNA in breast milk from 28 women who transmitted HIV-1 (Ts) postnatally and from 130 women who did not transmit HIV-1 (NTs) were lower for women receiving ZDV than for women receiving placebo. Levels of HIV-1 RNA in breast milk remained low over time in NTs but increased by 8-16-fold in Ts treated with ZDV from baseline to days 45/90 after delivery. Levels of HIV-1 RNA in breast milk at day 8 after delivery and the increase in levels of HIV-1 RNA in breast milk from day 8 to days 45/90 after delivery were independently associated with postnatal transmission. An increase in the levels of HIV-1 RNA in breast milk from day 8 to 45 after delivery was associated with maternal ZDV prophylaxis. The rebound in levels of HIV-1 RNA in breast milk after discontinuation of maternal antiretrovirals needs to be further explored--it may justify prolonging antiretroviral prophylaxis during the entire breast-feeding period.